Jonathan Z. Luo

Jonathan Z. Luo

Auto-generated profile, based on publicly available information

Jonathan Z. Luo

Department of Molecular and Functional Genomics

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Noura Abul-HusnNoura Abul-Husn
Noura Abul-Husn
XCXiping Cheng
Xiping Cheng
ALAlexander H. Li
Alexander H. Li
YXYurong Xin
Yurong Xin
CSClaudia Schurmann
Claudia Schurmann
FDFrederick E. Dewey
Frederick E. Dewey
Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. A splice variant (rs72613567:TA) in HSD17B13, encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, was found to be associated with reduced levels of ALT (P=4.2×10−12) and AST (P=6.2×10−10). Among DiscovEHR study participants, this variant was found to be associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. A loss-of-function variant in HSD17B13 is associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.)

8 August 2019 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
WBWhitney Besse
Whitney Besse
ACAlex R. Chang
Alex R. Chang
JLJonathan Z. Luo
Jonathan Z. Luo
WTWilliam J. Triffo
William J. Triffo
BMBryn S. Moore
Bryn S. Moore
TMTooraj Mirshahi
Tooraj Mirshahi
Significance Statement: Dominantly inherited polycystic kidney and liver phenotypes occur when epithelial cells in these organs have reduction of polycystin-1 functional dosage. In a cohort of genetically unresolved polycystic liver and kidney disease, the authors identified heterozygous loss of function mutations in ALG9. ALG9 encodes an endoplasmic reticulum enzyme that builds N-glycans, and the authors show that Alg9 inactivation results in impaired polycystin-1 maturation. Using a novel ‘genotype-first’ approach to ascertain individuals based strictly on their ALG9 genotype from a large cohort of exome-sequenced individuals, the authors find that 7/8 (88%) of ALG9 mutation carriers over age 50 have multiple kidney cysts. Together, these findings identify ALG9 as a novel human polycystic kidney and liver disease gene and support the utility of a genotype-driven approach to candidate disease gene validation and genotype-phenotype correlation. Background: Mutations in PKD1 or PKD2 cause typical autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic kidney disease. Dominantly inherited polycystic kidney and liver diseases on the ADPKD spectrum are also caused by mutations in at least six other genes required for protein biogenesis in the endoplasmic reticulum, the loss of which results in defective production of the PKD1 gene product, the membrane protein polycystin-1 (PC1). Methods: We used whole-exome sequencing in a cohort of 122 patients with genetically unresolved clinical diagnosis of ADPKD or polycystic liver disease to identify a candidate gene, ALG9, and in vitro cell-based assays of PC1 protein maturation to functionally validate it. For further validation, we identified carriers of ALG9 loss-of-function mutations and noncarrier matched controls in a large exome-sequenced population-based cohort and evaluated the occurrence of polycystic phenotypes in both groups. Results: Two patients in the clinically defined cohort had rare loss-of-function variants in ALG9, which encodes a protein required for addition of specific mannose molecules to the assembling N-glycan precursors in the endoplasmic reticulum lumen. In vitro assays showed that inactivation of Alg9 results in impaired maturation and defective glycosylation of PC1. Seven of the eight (88%) cases selected from the population-based cohort based on ALG9 mutation carrier state who had abdominal imaging after age 50; seven (88%) had at least four kidney cysts, compared with none in matched controls without ALG9 mutations. Conclusions: ALG9 is a novel disease gene in the genetically heterogeneous ADPKD spectrum. This study supports the utility of phenotype characterization in genetically-defined cohorts to validate novel disease genes, and provide much-needed genotype-phenotype correlations.

11 November 2016 in Behavioural Brain Research
Verified
Journal Article
Closed access
KBKevin T. Ball
Kevin T. Ball
OBOlivia Best
Olivia Best
JLJonathan Luo
Jonathan Luo
LMLeah R. Miller
Leah R. Miller

1 February 2018 in Biophysical Journal
Verified
Journal Article
Closed access
PDF file
CHCassandra M. Hartle
Cassandra M. Hartle
JLJonathan Z. Luo
Jonathan Z. Luo
ASAnn N. Stepanchick
Ann N. Stepanchick
UMUyenlinh L. Mirshahi
Uyenlinh L. Mirshahi
DHDustin N. Hartzel
Dustin N. Hartzel
TMTooraj Mirshahi
Tooraj Mirshahi

1 February 2018 in Biophysical Journal
Verified
Journal Article
Closed access
PDF file
BMBryn S. Moore
Bryn S. Moore
ASAnn N. Stepanchick
Ann N. Stepanchick
JLJonathan Z. Luo
Jonathan Z. Luo
TMTooraj Mirshahi
Tooraj Mirshahi

2 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ACAlexander R. Chang
Alexander R. Chang
BMBryn Moore
Bryn Moore
JLJonathan Z. Luo
Jonathan Z. Luo
GSGino Sartori
Gino Sartori
BFBrian Fang
Brian Fang
TMTooraj Mirshahi
Tooraj Mirshahi
Importance: Most studies of ADPKD genetics have used select cohorts, focusing on PKD1 and PKD2 and more recently several other cystic genes. However, the population prevalence of ADPKD and the contribution of each cystic gene to ADPKD are not well understood. Objective: Determine the prevalence of ADPKD, contribution of PKD1, PKD2 , and other cystic genes to ADPKD in a large, unselected cohort. Design, Setting, and Participants: We determined the prevalence of ADPKD In an unselected health system-based cohort of 173,954 subjects with the existing exome sequencing and extensive electronic health records, including abdominal imaging. The presence of genetic variants in PKD1, PKD2 , and eleven other cystic genes was evaluated. Rare genetic variants were identified in patients with chart review confirmed diagnosis of ADPKD. Main Outcomes: Diagnosis of ADPKD and presences of rare (AF<0.0001) missense, protein-truncating variants (PTVs), or copy number variants deletions (CNV) in PKD1, PKD2 , or PTVs and CNVs in the following 11 genes: ALG8, ALG9, DNAJB11, GANAB, HNF1B, IFT140, LRP5, PKHD1, PRKCSH, SEC61B , and SEC63 . Results: Among 173,954 patients, there were 235 patients with chart review confirmed ADPKD (0.135%). Among patients with PTV or CNV in PKD1 , 66/70 (94.2%) had ADPKD and 43/44 (97.7%) of patients with PTV or CNV in PKD2 had ADPKD. In contrast, only 24/77 (31.2%) patients with a PKD1 missense variant previously classified as “likely pathogenic” had ADPKD. A rare variant was identified in a cystic gene in 180/235 (76.6%) of ADPKD patients, with the most common genes implicated PKD1 (127) and PKD2 (34) and then IFT140 (7), PKHD1 (3), GANAB (4), HNF1B (2), ALG8 (1), ALG9 (1), IFT140 + PKHD1 (1). The yield for a genetic determinant of ADPKD was 91.3% among those with a family history compared to 50.6% among those without a family history (p<0.0001). We report several previously unreported variants where pedigree data suggest pathogenicity. Atypical cystic genes ALG8, ALG9, GANAB, HNF1B, IFT140 , and SEC63 were associated with having any kidney or liver cystic ICD code, but not diagnosed ADPKD. Conclusions: Exome sequencing established the molecular diagnosis for the vast majority of patients with ADPKD, revealed a wider range of ADPKD with atypical cystic genes. Additional population-based research cohorts are needed to carefully curate missense PKD1 variants and variants in atypical cystic genes.